2. Search Result
Search Result
Results for "

Aminobenzenesulfonic auristatin E-d<sub>8</sub>

" in MedChemExpress (MCE) Product Catalog:

4419

Inhibitors & Agonists

1

Screening Libraries

4

Fluorescent Dye

16

Biochemical Assay Reagents

31

Peptides

2

MCE Kits

12

Inhibitory Antibodies

18

Natural
Products

18

Recombinant Proteins

4216

Isotope-Labeled Compounds

16

Antibodies

21

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145989S
    Aminobenzenesulfonic auristatin E-d8

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic auristatin E-d8
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic auristatin E TFA
  • HY-12522S
    PF-06380101-d8
    2 Publications Verification

    Aur0101-d<sub>8sub>; auristatin-0101-d<sub>8sub>

    		 Microtubule/Tubulin ADC Payload Cancer
    PF-06380101-d8 is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue .
    PF-06380101-d8
  • HY-W015302
    2-Aminobenzenesulfonic acid

    Orthanilic acid; 2-Aminobenzenesulphonic acid

    		 Drug Intermediate Others
    2-Aminobenzenesulfonic acid (Orthanilic acid) is an amine derivative. 2-Aminobenzenesulfonic can be used for the synthesis of other active compounds. 2-Aminobenzenesulfonic acid can be converted into Schiff base, and further used for the preparation of metal complexes .
    2-Aminobenzenesulfonic acid
  • HY-15162A
    MMAE-d8
    5+ Cited Publications

    Monomethyl auristatin E-d<sub>8sub>; Deuterated labeled MMAE

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    MMAE-d8
  • HY-145989
    Aminobenzenesulfonic auristatin E

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic auristatin E
  • HY-162068
    Auristatin23

    		Drug Derivative Cancer
    Auristatin23, a conjugate of Auristatin F (HY-15583), is a cytotoxin. Auristatin23 exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ .
    Auristatin23
  • HY-15582G
    Auristatin E

    		Microtubule/Tubulin ADC Payload Cancer
    Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .
    Auristatin E
  • HY-164107
    Auristatin S

    		ADC Payload Microtubule/Tubulin Cancer
    Auristatin S is an Auristatin payload with potent antitumor activity. Auristatin S attenuates bystander activity with improved off-target toxicity. Auristatin S has excellent tolerability in Karpas/KarpasBVR cell models. Auristatin S can be used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types .
    Auristatin S
  • HY-146227
    DNA topoisomerase II inhibitor 1

    		Topoisomerase Apoptosis Cancer
    DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase .
    DNA topoisomerase II inhibitor 1
  • HY-RS13999
    SUB1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUB1 Human Pre-designed siRNA Set A
    SUB1 Human Pre-designed siRNA Set A
  • HY-RS18793
    Sub1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sub1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sub1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sub1 Mouse Pre-designed siRNA Set A
    Sub1 Mouse Pre-designed siRNA Set A
  • HY-RS25282
    Sub1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sub1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sub1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sub1 Rat Pre-designed siRNA Set A
    Sub1 Rat Pre-designed siRNA Set A
  • HY-15575S
    VcMMAE-d8

    MC-Val-Cit-PAB-MMAE-d<sub>8sub>; mc-vc-PAB-MMAE-d<sub>8sub>

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
    VcMMAE-d8
  • HY-15583
    Auristatin F

    		ADC Payload Microtubule/Tubulin Cancer
    Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F
  • HY-10844S1
    Pretomanid-d5

    PA-824-d<sub>5sub>; (S)-PA 824-d<sub>5sub>

    		 Antibiotic Bacterial Isotope-Labeled Compounds Infection Cancer
    Pretomanid-d5 is deuterated labeled Pretomanid (HY-10844). Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
    Pretomanid-d5
  • HY-15583S
    Auristatin F-d8

    		Isotope-Labeled Compounds ADC Payload Microtubule/Tubulin Cancer
    Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F-d8
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Payload Cancer
    Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
    Auristatin E
  • HY-P10215
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2

    		Parasite Infection
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2 (compound 40) is a potent Plasmodium subtilisin-like protease 1 (SUB1) inhibitor. SUB1-IN-1 shows IC50 values of 12 nM and 10 nM against P. vivax and P. falciparum SUB1 (Pv- and PfSUB1), respectively .
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2
  • HY-N7148S
    α-Vitamin E-d6

    (+)-α-Tocopherol-d<sub>6sub>; D-α-Tocopherol-d<sub>6sub>

    		 COX Endogenous Metabolite Isotope-Labeled Compounds Others
    α-Vitamin E-d6 is the deuterium labeled α-Vitamin E .
    α-Vitamin E-d6
  • HY-17037S1
    Pirenzepine-d8 dihydrochloride

    LS 519-d<sub>8sub> dihydrochloride; Pirenzepin-d<sub>8sub> dihydrochloride; Gastrozepin-d<sub>8sub> dihydrochloride

    		 Isotope-Labeled Compounds mAChR Cancer
    Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
    Pirenzepine-d8 dihydrochloride
  • HY-G0021S
    N-Desmethylclozapine-d8

    Norclozapine-d<sub>8sub>; Desmethylclozapine-d<sub>8sub>; Normethylclozapine-d<sub>8sub>

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist .
    N-Desmethylclozapine-d8
  • HY-G0021S1
    N-Desmethylclozapine-d8 hydrochloride

    Norclozapine-d<sub>8sub> hydrochloride; Desmethylclozapine-d<sub>8sub> hydrochloride; Normethylclozapine-d<sub>8sub> hydrochloride

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist .
    N-Desmethylclozapine-d8 hydrochloride
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d<sub>8sub>; Ethmozin-d<sub>8sub>; Moracizine-d<sub>8sub>

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .
    Moricizine-d8(Hydrochloride)
  • HY-134928AS
    Pyridinium bisretinoid A2E-d4 TFA

    A2E-d<sub>4sub> TFA

    		 Isotope-Labeled Compounds Cancer
    Pyridinium bisretinoid A2E-d4 TFA is the deuterium-labeled Pyridinium bisretinoid A2E (HY-134928). Pyridinium bisretinoid A2E (A2E)is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E mediates autophagy and the production of reactive oxygen species .
    Pyridinium bisretinoid A2E-d4 TFA
  • HY-W748758
    (Z)-Thiothixene-d8

    NSC 108165-d<sub>8sub>; Navan-d<sub>8sub>; Navane-d<sub>8sub>

    		 Isotope-Labeled Compounds Dopamine Receptor Histamine Receptor mAChR Adrenergic Receptor Sigma Receptor Others
    (Z)-Thiothixene-d8 (NSC 108165-d8; Navan-d8; Navane-d8) is the deuterium labeled Thiothixene (HY-A0139). Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
    (Z)-Thiothixene-d8
  • HY-78903A
    Monomethyl auristatin E intermediate-10

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-10 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-10
  • HY-78899
    Monomethyl auristatin E intermediate-6

    		Microtubule/Tubulin Drug Intermediate Cancer
    Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-6
  • HY-78901
    Monomethyl auristatin E intermediate-7

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-7 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-7
  • HY-78908
    Monomethyl auristatin E intermediate-11

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-11 is an intermediate reactant in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-11
  • HY-33048
    Monomethyl auristatin E intermediate-1

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-1 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-1
  • HY-78903
    Monomethyl auristatin E intermediate-9

    		Microtubule/Tubulin Drug Intermediate Cancer
    Monomethyl auristatin E intermediate-9 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-9
  • HY-78901A
    Monomethyl auristatin E intermediate-8

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-8 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-8
  • HY-78911
    Monomethyl auristatin E intermediate-13

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-13 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-13
  • HY-79196
    Monomethyl auristatin E intermediate-15

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-15 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-15
  • HY-79198
    Monomethyl auristatin E intermediate-16

    		Microtubule/Tubulin Drug Intermediate ADC Payload Cancer
    Monomethyl auristatin E intermediate-16 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-16
  • HY-78910
    Monomethyl auristatin E intermediate-12

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-12 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-12
  • HY-43147
    Monomethyl auristatin E intermediate-4

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-4 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-4
  • HY-79205
    Monomethyl auristatin E intermediate-17

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-17 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-17
  • HY-49413
    Monomethyl auristatin E intermediate-2

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-2 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-2
  • HY-43149
    Monomethyl auristatin E intermediate-5

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-5 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-5
  • HY-78913
    Monomethyl auristatin E intermediate-14

    		ADC Payload Cancer
    Monomethyl auristatin E intermediate-14 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-14
  • HY-43146
    Monomethyl auristatin E intermediate-3

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-3 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-3
  • HY-50896S3
    Erlotinib-d8

    CP-358774-d<sub>8sub>; NSC 718781-d<sub>8sub>; OSI-774-d<sub>8sub>

    		 Isotope-Labeled Compounds Cancer
    Erlotinib-d8 (CP-358774-d8) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Erlotinib-d8
  • HY-13463BS
    Avatrombopag-d8 hydrochloride

    AKR-501-d<sub>8sub> hydrochloride; E5501-d<sub>8sub> hydrochloride; YM477-d<sub>8sub> hydrochloride

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Cardiovascular Disease
    Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag-d8 hydrochloride
  • HY-14740S
    Elvitegravir-d8

    GS-9137-d<sub>8sub>; JTK-303-d<sub>8sub>; D06677-d<sub>8sub>

    		 Isotope-Labeled Compounds HIV Integrase HIV Infection
    Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-d8
  • HY-17037S
    Pirenzepine-d8

    LS 519-d<sub>8sub> free base; Pirenzepin-d<sub>8sub>; Gastrozepin-d<sub>8sub>

    		 Isotope-Labeled Compounds mAChR Neurological Disease Inflammation/Immunology
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d8
  • HY-10227S
    Bortezomib-d8

    PS-341-d<sub>8sub>; LDP-341-d<sub>8sub>; NSC 681239-d<sub>8sub>

    		 Proteasome NF-κB Apoptosis Autophagy Cancer
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .
    Bortezomib-d8
  • HY-10570S2
    Nevirapine-d8

    BI-RG 587-d<sub>8sub>; NSC 641530-d<sub>8sub>; NVP-d<sub>8sub>

    		 Isotope-Labeled Compounds Reverse Transcriptase Parasite HIV Infection Cancer
    Nevirapine-d8 (BI-RG 587-d8) is deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a Ki of 270 μM .
    Nevirapine-d8
  • HY-15531S
    Venetoclax-d8

    ABT-199-d<sub>8sub>; GDC-0199-d<sub>8sub>; RG7601-d<sub>8sub>

    		 Bcl-2 Family Autophagy Cancer
    Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
    Venetoclax-d8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: